Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies

O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale… - Cancer discovery, 2014 - AACR
O Abdel-Wahab, VM Klimek, AA Gaskell, A Viale, D Cheng, E Kim, R Rampal, M Bluth…
Cancer discovery, 2014AACR
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAFV600-mutant
melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS-
mutant cells. In a patient with a BRAFV600K-mutant melanoma responding to vemurafenib,
we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia.
We hypothesized that combining vemurafenib with a MAP–ERK kinase (MEK) inhibitor
would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in …
Abstract
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAFV600-mutant melanoma but activates extracellular signal–regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAFV600K-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP–ERK kinase (MEK) inhibitor would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in the leukemia, and thus suppress both malignancies. We demonstrate that intermittent administration of vemurafenib led to a near-complete remission of the melanoma, and the addition of the MEK inhibitor cobimetinib (GDC-0973) caused suppression of vemurafenib-induced leukemic proliferation and ERK activation. Antimelanoma and antileukemia responses have been maintained for nearly 20 months, as documented by serial measurements of tumor-derived DNA in plasma in addition to conventional radiographic and clinical assessments of response. These data support testing of intermittent ERK pathway inhibition in the therapy for both RAS-mutant leukemia and BRAF-mutant melanoma.
Significance: We show that in a patient with simultaneous RAS-mutant leukemia and BRAF-mutant melanoma, intermittent RAF inhibitor therapy induced a near-complete melanoma response, and addition of a MEK inhibitor prevented RAF inhibitor-induced activation of the RAS-mutant leukemia. Intermittent therapy may permit greater pathway inhibition with less toxicity, avoid chronic relief of pathway feedback, and have enhanced effectiveness compared with chronic administration. Cancer Discov; 4(5); 538–45. ©2014 AACR.
See related commentary by Davies, p. 510
This article is highlighted in the In This Issue feature, p. 495
AACR